bioAffinity Technologies Warrant Company Z Score Analysis
BioAffinity Technologies' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| First Factor | = | 1.2 * ( | Working Capital | / | Total Assets ) |
|
| Second Factor | = | 1.4 * ( | Retained Earnings | / | Total Assets ) |
|
| Thrid Factor | = | 3.3 * ( | EBITAD | / | Total Assets ) |
|
| Fouth Factor | = | 0.6 * ( | Market Value of Equity | / | Total Liabilities ) |
|
| Fifth Factor | = | 0.99 * ( | Revenue | / | Total Assets ) |
|
BioAffinity Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for BioAffinity Technologies is extremely important. It helps to project a fair market value of BioAffinity Stock properly, considering its historical
fundamentals such as Z Score. Since BioAffinity Technologies' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of BioAffinity Technologies' historical
financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of BioAffinity Technologies' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
In accordance with the company's disclosures, bioAffinity Technologies Warrant has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the
Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
BioAffinity Z Score Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses BioAffinity Technologies' direct or indirect competition against its Z Score to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of BioAffinity Technologies could also be used in its relative valuation, which is a method of valuing BioAffinity Technologies by comparing valuation metrics of similar companies.
BioAffinity Technologies is currently under evaluation in z score category among its peers.
BioAffinity Fundamentals
About BioAffinity Technologies Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze bioAffinity Technologies Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioAffinity Technologies using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of bioAffinity Technologies Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our
fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to
measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to
predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.